Other long term (current) drug therapy
Notes: Long term (current) use of raloxifene (Evista) ; Long term (current) use of tamoxifen (Nolvadex) ; Long term (current) use of toremifene (Fareston) ; Long term (current) use of anastrozole (Arimidex) ; Long term (current) use of exemestane (Aromasin) ; Long term (current) use of letrozole (Femara) ; Long term (current) use of estrogen receptor downregulators ; Long term (current) use of fulvestrant (Faslodex) ; Long term (current) use of gonadotropin-releasing hormone (GnRH) agonist ; Long term (current) use of goserelin acetate (Zoladex) ; Long term (current) use of leuprolide acetate (leuprorelin) (Lupron) ; Long term (current) use of megestrol acetate (Megace) ; Long term (current) use of oral antidiabetic drugs ; Long term (current) use of methadone for pain management ; code, if applicable, to identify: ; estrogen receptor positive status (Z17.0) ; family history of breast cancer (Z80.3) ; genetic susceptibility to malignant neoplasm (cancer) (Z15.0-) ; personal history of breast cancer (Z85.3) ; personal history of prostate cancer (Z85.46) ; postmenopausal status (Z78.0) ; hormone replacement therapy (Z79.890) ; methodone use NOS (F11.9-) ; use of methodone for treatment of heroin addiction (F11.2-) ; long-term (current) use of injectable non-insulin antidiabetic drugs (Z79.85) ; long term (current) use of insulin (Z79.4) ; long term (current) use of insulin (Z79.4) ; long term (current) use of oral hypoglycemic drugs (Z79.84) ; , if applicable: ; malignant neoplasm of breast (C50.-) ; malignant neoplasm of prostate (C61)